Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.

Published

Journal Article

In order to explore non-cisplatin containing regimens for advanced non-small cell lung cancer, Cancer and Leukemia Group B conducted a randomized Phase-II study of two novel combinations, paclitaxel/ifosfamide and vinorelbine/ifosfamide. Both regimens were active with a 38% response rate (95% CI: 24%, 53%) and 31% (95% CI: 18%, 47%), respectively. Median survivals were 8.5 and 7.4 months. Toxicity, mostly neutropenia, was acceptable. These two combinations establish a 'proof of principle' that non-cisplatin containing regimens also have activity in this setting.

Full Text

Duke Authors

Cited Authors

  • Perry, MC; Ihde, DC; Herndon, JE; Grossbard, ML; Grethein, SJ; Atkins, JN; Vokes, EE; Green, MR

Published Date

  • April 2000

Published In

Volume / Issue

  • 28 / 1

Start / End Page

  • 63 - 68

PubMed ID

  • 10704711

Pubmed Central ID

  • 10704711

Electronic International Standard Serial Number (EISSN)

  • 1872-8332

International Standard Serial Number (ISSN)

  • 0169-5002

Digital Object Identifier (DOI)

  • 10.1016/s0169-5002(99)00129-4

Language

  • eng